Bionano Genomics Files 8-K on Shareholder Votes
Ticker: BNGO · Form: 8-K · Filed: Dec 2, 2024 · CIK: 1411690
| Field | Detail |
|---|---|
| Company | Bionano Genomics, Inc. (BNGO) |
| Form Type | 8-K |
| Filed Date | Dec 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, 8-k
Related Tickers: BNGO
TL;DR
BNGO filed an 8-K on Nov 27 for shareholder votes - watch for governance changes.
AI Summary
Bionano Genomics, Inc. filed an 8-K on November 27, 2024, to report on matters submitted to a vote of its security holders. The filing details the company's corporate actions and decisions made by its shareholders.
Why It Matters
This filing indicates significant corporate governance events, such as shareholder approvals for key company decisions, which can impact the company's strategic direction and investor confidence.
Risk Assessment
Risk Level: low — This is a routine filing reporting on shareholder votes, not indicating immediate financial distress or significant operational changes.
Key Players & Entities
- Bionano Genomics, Inc. (company) — Registrant
- November 27, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-38613 (filing_id) — SEC File Number
- 26-1756290 (tax_id) — IRS Employer Identification No.
- 9540 Towne Centre Drive, Suite 100 San Diego, California 92121 (address) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of Bionano Genomics' security holders?
The filing states that matters were submitted to a vote of security holders, but the specific details of these matters are not enumerated in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on November 27, 2024.
What is Bionano Genomics, Inc.'s state of incorporation?
Bionano Genomics, Inc. is incorporated in Delaware.
What is the SEC File Number for Bionano Genomics, Inc.?
The SEC File Number for Bionano Genomics, Inc. is 001-38613.
Where are Bionano Genomics, Inc.'s principal executive offices located?
Bionano Genomics, Inc.'s principal executive offices are located at 9540 Towne Centre Drive, Suite 100, San Diego, California 92121.
Filing Stats: 583 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-12-02 16:54:52
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share BNGO The Nasdaq Sto
Filing Documents
- bngo-20241127.htm (8-K) — 26KB
- 0001411690-24-000066.txt ( ) — 146KB
- bngo-20241127.xsd (EX-101.SCH) — 2KB
- bngo-20241127_lab.xml (EX-101.LAB) — 21KB
- bngo-20241127_pre.xml (EX-101.PRE) — 12KB
- bngo-20241127_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On November 27, 2024, Bionano Genomics, Inc. (the "Company") held its 2024 Special Meeting of Stockholders (the "Special Meeting"), which had been previously adjourned for lack of quorum on October 2, 2024 and October 30, 2024. As of August 12, 2024, the record date for the Special Meeting (the "Record Date"), 85,997,130 shares of the Company's common stock were outstanding and entitled to vote at the Special Meeting. A summary of the matter voted upon by stockholders at the Special Meeting is set forth below. A total of 30,467,764 shares of the Company's common stock were present at the Special Meeting in person, by virtual attendance, or by proxy, which represents approximately 35.42% of the shares of the Company's common stock outstanding as of the Record Date. Proposal 1. Approval of the Issuance of Shares of Common Stock Issuable Upon Exercise of Warrants. The Company's stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of up to an aggregate of 35,026,272 shares of common stock issuable upon the exercise of certain Series A warrants and Series B warrants issued in connection with a private placement pursuant to the securities purchase agreement, dated July 4, 2024, between the Company and certain institutional investors thereto. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 22,919,968 6,162,679 1,385,117 0
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Bionano Genomics, Inc. Date: December 2, 2024 By: /s/ R. Erik Holmlin, Ph.D. R. Erik Holmlin, Ph.D. President and Chief Executive Officer (Principal Executive Officer)